NCT05166122 is a NA clinical trial of Artificial Intelligence in Diabetic Retinopathy, sponsored by Department of Medical Services Ministry of Public Health of Thailand.

Who is sponsoring NCT05166122?

NCT05166122 is sponsored by Department of Medical Services Ministry of Public Health of Thailand.

What drugs are being tested in NCT05166122?

Interventions in NCT05166122: Artificial Intelligence.

What condition does NCT05166122 study?

NCT05166122 studies Diabetic Retinopathy, Artificial Intelligence, Screening.

Is NCT05166122 still recruiting?

NCT05166122 is currently status unknown. Last updated 2 September 2022.

Last reviewed 2022-09-02 · How we verify

NCT05166122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Implementation of an Integrated System of Artificial Intelligence and Referral Tracking for Real-time Diabetic Retinopathy Screening

Status unknown NA Last updated 2 September 2022

What this trial tests

NA trial testing Artificial Intelligence in Diabetic Retinopathy in 1,600 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
19 August 2022

30 September 2022

Quick facts

Lead sponsor	Department of Medical Services Ministry of Public Health of Thailand
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	1,600
Start date	1 January 2022
Primary completion	19 August 2022
Estimated completion	30 September 2022
Sites	1 location across Thailand

Drugs / interventions tested

Artificial Intelligence

Conditions studied

Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
Artificial Intelligence — all drugs for Artificial Intelligence →
Screening — all drugs for Screening →

Sponsor

Department of Medical Services Ministry of Public Health of Thailand

Who can join

18 and older, any sex, with Diabetic Retinopathy or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study aims to bring an artificial intelligence system to screen for diabetic retinopathy (DR) along with referral tracking systems to the screening unit in Uthai Hospital in Phra Nakhon Sri Ayutthaya to assess the effectiveness of screening and follow-up of patients referred to Phra Nakhon Sri Ayutthaya Hospital. It will be compared with the existing screening system and follow up with regular referral by personnel

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transforming Non-Digital, Clinical Workflows to Detect and Track Vision-Threatening Diabetic Retinopathy via a Digital Platform Integrating Artificial Intelligence: Implementation Research.
Chotcomwongse P, Ruamviboonsuk P, Karavapitayakul C, Thongthong K, et al · · 2025 · cited 2× · PMID 39792334 · DOI 10.1007/s40123-024-01086-8

Verify or expand the search:

Other trials of Artificial Intelligence

Trials testing the same drug.

NCT07189520 — 1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestin · not yet recruiting
NCT07265154 — Gait Training and Artificial Intelligence · NA · recruiting
NCT06770985 — Effectiveness of Artificial Intelligence Algorithms · completed
NCT06839261 — Evaluation of Double Lumen Tube Intubation Difficulty With Photo-Based Artificial Intelligence Algorithms · completed
NCT06517082 — Ambient AI for Provider Well-Being · NA · completed

Other recruiting trials for Diabetic Retinopathy

Currently open trials in the same condition.

NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes · NA · recruiting
NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
NCT06713720 — Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy · NA · recruiting
NCT06892353 — AI-Powered DIY Screening System for Diabetic Retinopathy · NA · recruiting

Other Department of Medical Services Ministry of Public Health of Thailand trials

Trials by the same sponsor.

NCT06665737 — Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients · Phase 4 · not yet recruiting
NCT06763575 — Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy · NA · recruiting
NCT06860659 — Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient With Moderate to Severe Dry Eye · Phase 4 · enrolling by invitation
NCT06525870 — Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Control · Phase 2 · enrolling by invitation
NCT06436833 — Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Gl · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05166122 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Department of Medical Services Ministry of Public Health of Thailand
Last refreshed: 2 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing